Premium
Potential Angiotensin‐Converting Enzyme Inhibitor—Epoetin Alfa Interaction in Patients Receiving Chronic Hemodialysis
Author(s) -
Schwenk Michael H.,
Jumani Abdul Q.,
Rosenberg Carl R.,
Kulogowski Josephine E.,
Charytan Chaim,
Spinowitz Bruce S.
Publication year - 1998
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1002/j.1875-9114.1998.tb03126.x
Subject(s) - medicine , captopril , hemodialysis , enalapril , hematocrit , angiotensin converting enzyme , gastroenterology , epoetin alfa , ace inhibitor , dose , darbepoetin alfa , urology , erythropoietin , blood pressure
We compared epoetin alfa (EPO) dose requirements and hematocrit response in 17 patients receiving chronic hemodialysis at baseline and after 3 and 12 months of therapy with angiotensin‐converting enzyme (ACE) inhibitors (12 enalapril, 5 captopril). No acute processes were present (infection, hemorrhage, inflammation) at time of starting ACE inhibitor therapy. Mean (± SD) intravenous EPO dosages at zero, 3, and 12 months were 6012 ± 2575, 5800 ± 2026, and 5660 ± 2285 U 3 times/week (p=0.56), and mean differences were − 212 U for 0–3 months (95% CI −1310 to 886) and −713 U for 0–12 months (95% CI −2142 to 716). Mean ± SD hematocrits were 30.5 ± 3.9%, 31.6 ± 3.2%, and 34.2 ± 3.1% (p=0.01, zero vs 12 mo), and mean differences were 1.7% for 0–3 months (95% CI −1.41 to 4.81) and 3.85% for zero–12 months (95% CI 0.71–7). Our results indicate that ACE inhibitors do not increase EPO dose requirements or reduce hematocrits in these patients.